BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20280326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20281029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250425T000000
DTEND;TZID=Europe/Vienna:20260425T235959
DTSTAMP:20260421T154811
CREATED:20250225T141140Z
LAST-MODIFIED:20250605T144111Z
UID:2257-1745539200-1777161599@esmit.eanm.org
SUMMARY:Highlights of Focus Meeting 6: Shaping the Future of Breast Cancer Care with Molecular Imaging
DESCRIPTION:Breast cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death in women worldwide. Despite significant advancements in imaging and treatment\, clinical practice remains heterogeneous across institutions and disciplines. Molecular imaging has a pivotal role in breast cancer care\, from diagnosis to recurrence assessment. To address these discrepancies and define the future direction of imaging in breast cancer\, the European Association of Nuclear Medicine (EANM) devoted its 6th Focus Meeting to this topic\, under the following motto “Shaping the Future of Breast Cancer Care with Molecular Imaging”. \n\n\n\n \n\n\n\nThe aims of this project were: \n\n\n\n\nTo define the role of imaging in breast cancer\, particularly the utility of nuclear medicine techniques in different clinical settings (including initial systemic staging\, assessment of response to therapy\, and detection of recurrence). \n\n\n\nTo reach a multidisciplinary consensus on the current state of the art in nuclear medicine imaging in breast cancer.\n\n\n\nTo generate expert recommendations on how best to guide professionals in their clinical decisions\, beyond the existing guidelines. \n\n\n\nTo identify knowledge gaps and topics with lack of scientific evidence for potential future studies.\n\n\n\n\n \n\n\n\n \n\n\n\nThe recordings in this course are sponsored by Novartis. \n\n\n\n\n\n\n\n\n\nRegister nowEnrol in the online course now for free! Register now\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\n\nIsabel T. RubioSpeaker \n\n\n\n\n\nFrederique Penault LlorcaSpeaker \n\n\n\n\n\nThiemo van NijnattenSpeaker \n\n\n\n\n\nElizabeth DibbleSpeaker \n\n\n\n\n\nTessa BuckleSpeaker \n\n\n\n\n\nKatja Pinker DomenigSpeaker \n\n\n\n\n\n\n\n\n\nSofia Carrilho-VazSpeaker \n\n\n\n\n\nMartina Bašić-KoretićSpeaker \n\n\n\n\n\nDavid GroheuxSpeaker \n\n\n\n\n\nGary UlanerSpeaker \n\n\n\n\n\nGeraldine GebhartSpeaker \n\n\n\n\n\nWolfgang WeberSpeaker \n\n\n\n\n\n\n\n\n\nValeria RomeoSpeaker \n\n\n\n\n\nAlessandra GennariSpeaker \n\n\n\n\n\nKarolien GoffinSpeaker \n\n\n\n\n\nNadia HarbeckSpeaker \n\n\n\n\n\nPascal BaltzerSpeaker \n\n\n\n\n\nMichel van KruchtenSpeaker \n\n\n\n\n\n\n\n\n\nGary Cook Speaker \n\n\n\n\n\nPaola Anna ErbaSpeaker \n\n\n\n\n\nJoana M RibeiroSpeaker \n\n\n\n\n\nCarolien SchröderSpeaker \n\n\n\n\n\nRitse MannSpeaker \n\n\n\n\n\nPhilipp BackhausSpeaker \n\n\n\n\n\n\n\n\n\nMalene Gubbe Hildebrand Speaker \n\n\n\n\n\nFatima CardosoSpeaker \n\n\n\n\n\nAntoinette AttardSpeaker \n\n\n\n\n\nFrancesco SchnettiniSpeaker \n\n\n\n\n\nSofia RiveraSpeaker \n\n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/highlights-of-focus-meeting-6-shaping-the-future-of-breast-cancer-care-with-molecular-imaging/
LOCATION:Online
CATEGORIES:Clinical Nuclear Medicine,Self-paced Online Course
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251030T080000
DTEND;TZID=Europe/Vienna:20271130T170000
DTSTAMP:20260421T154811
CREATED:20240228T100725Z
LAST-MODIFIED:20251118T083202Z
UID:1520-1761811200-1827594000@esmit.eanm.org
SUMMARY:Bringing Alpha Therapies into Clinical Practice
DESCRIPTION:UEMS EACCME has granted the accreditation of 3 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nThis online course offers a comprehensive introduction to alpha therapy in nuclear medicine\, with a focus on the fundamental principles and clinical applications of Alpha-Therapy in the fields of Radiopharmaceutical Sciences\, Oncology and Dosimetry. Alpha Therapy is a cutting-edge cancer treatment using alpha radiation. It represents a form of targeted radionuclide therapy that uses alpha-emitting radioisotopes to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. It is highly efficient and lately increasingly explored for scientific purposes in the oncologic domain . With this course we aim at bringing Alpha Therapies into clinical practice through various\, relevant presentations. A panel of experts and EANM members will update you on the type of alpha-emitting radioisotopes available\, describing all important steps required for production and radiopharmaceutical development. The advantages\, but also the challenges related to the use of Alpha therapy will amply be discussed and supported by clinical examples. You will be initiated in the existing and ongoing therapeutic trials\, with the best yet to come. Dosimetry will play a pivotal role in this course\, underlying its role in clinical practice. Finally\, The Alphamet project will be presented\, allowing you to get updated with the latest insights from Theranostics. \n\n\n\n \n\n\n\nRPH \n\n\n\nTargeted Alpha Therapy (TAT) represents a cutting-edge advancement in cancer treatment\, harnessing the potent\, cell-killing power of alpha particles to precisely destroy malignant cells while minimizing damage to surrounding healthy tissue. This part of the course course explores the transformative potential of TAT\, highlighting its exceptional potency\, unique ability to overcome radio-resistance\, and its role in modern theranostics. You’ll gain insight into the selection of optimal alpha-emitting radionuclides\, the biological advantages of short-range high-energy emissions\, and the complex challenges involved in the development\, production\, and clinical translation of these innovative therapies. Join us to deepen your knowledge and be part of the future of targeted radiopharmaceuticals in oncology. \n\n\n\nOncology \n\n\n\n \n\n\n\nIn this part of the course\, participants will explore the main advantages of alpha-emitting radionuclides in oncology\, while also gaining an understanding of the clinical challenges associated with their use. You will become familiar with the key clinical aspects of Alpha-Therapy\, supported by real-world perspectives and case insights. The course also highlights current and upcoming therapeutic trials\, providing valuable knowledge on the future direction of this rapidly evolving field. \n\n\n\nDosimetry \n\n\n\nParticipants will begin by exploring the basic concepts of dosimetry with alpha emitters\, highlighting key differences from beta emitter dosimetry. The course then delves into the clinical relevance of alpha dosimetry\, demonstrating how accurate dose assessments can inform and optimize the management of patients undergoing treatment with alpha radiotherapeutics. In addition\, the course presents the Alphamet project\, a major European initiative that addresses the specific metrological challenges associated with targeted alpha therapies. By examining the goals and contributions of Alphamet\, learners will gain insight into how this research supports the safe and effective integration of alpha therapy into routine clinical practice. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo gain an overview of the main advantages of Alpha-radionuclides\n\n\n\nTo learn about the challenges of alpha emitters\, complex production; transport issues\, waste management and handling\n\n\n\nTo get insights on radiobiology: radiotoxicity & effectiveness\n\n\n\nTo have a comprehensive review of research candidates\n\n\n\nTo provide an overview of the main advantages when using Alpha-Therapy in clinical practice\n\n\n\nTo learn about the clinical challenges when using Alpha-Therapy\n\n\n\nTo get insights into current and future trials focusing on Alpha-Therapy\n\n\n\nTo learn the most basic aspects about dosimetry of alpha emitters showing the main differences with dosimetry of beta emitters\n\n\n\nTo learn how dosimetry results could be used in the management of patients treated with radiopharmaceuticals that include alpha emitters\n\n\n\nTo learn on the Alphamet project\, which addresses the unique and unmet metrological challenges of targeted alpha therapies\, contributing to their safe and optimised implementation into routine clinical practice\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear medicine physicians\, radiologists\, medical oncologists\, urologists\, radiation oncologists\, medical physicists\, biologists\, researchers\n\n\n\nRadiochemists\, radiopharmacists\, physicists\, medical physicists\, biologists\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeClick to see the full event programme. View the Programme\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n\n\nDana NiculaeSpeaker \n\n\n\n\n\nEmma AnaheimSpeaker \n\n\n\n\n\nJanke KleyhansSpeaker \n\n\n\n\n\nMarianna TosatoSpeaker \n\n\n\n\n\nWolfgang FendlerSpeaker \n\n\n\n\n\nMathias ZacherlSpeaker \n\n\n\n\n\n\n\nPablo Mínguez GabiñaSpeaker \n\n\n\n\n\nMike SathekgeSpeaker \n\n\n\n\n\nDaniela Oprea-LagerSpeaker \n\n\n\n\n\nAna Denis-BacelarSpeaker \n\n\n\n\n\nJoe O’SullivanSpeaker \n\n\n\n\n\n\n\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\nEnroll yourselfFind your desired course under ‘Online Courses’  \n\n\n\nEnjoy!Once enrolled\, you get full access to the course contents on the ESMIT eLearning platform \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/bringing-alpha-therapies-into-clinical-practice-2/
LOCATION:Online
CATEGORIES:Clinical Nuclear Medicine,Online Course,Radiopharmaceuticals,Self-paced Online Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251107T133000
DTEND;TZID=Europe/Vienna:20251107T143000
DTSTAMP:20260421T154811
CREATED:20241017T081503Z
LAST-MODIFIED:20251104T110112Z
UID:1940-1762522200-1762525800@esmit.eanm.org
SUMMARY:Nuclear Medicine-related Highlights from ESMO 2025
DESCRIPTION:This ESMO 2025 webinar will cover a range of topics\, including the latest advancements treatment options\, imaging modalities and performant tracers related to solid and liquid tumors. The focus of this Live event will be the recent advances in solid & liquid tumor treatment\, clinical trials and emerging therapies\, biomarkers in solid tumors and multidisciplinary approaches. The importance of collaboration among medical oncologists\, radiologists\, nuclear medicine physicians\, pathologists and surgeons will be underlined\, based on clinical examples. Challenges and opportunities in immunotherapy for solid tumors will also be addressed\, with special attention for personalized treatment plans in specific cancers\, like lung cancer\, breast cancer\, colorectal and prostate cancer. \n\n\n\nPlease note that the webinar will be recorded\, and the recording will be available a few days after the session is over. You can find the recording on the ESMIT E-learning platform\, under the webinar title. A handout of the presentation materials will also be available on the platform. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nAttendees will get insight into recent advances in solid/ liquid tumor treatment\n\n\n\nAttendees will be familiarized with the latest developments when diagnosing\, staging and treating different types of solid and liquid tumors.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nFellows and Medical Specialists in Nuclear Medicine\, Radiology\, Medical Oncology\, Urology\, Surgery\, Pathology and Radiation Oncology\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nDavid KerstingModerator \n\n\n\n\n\nKarolien GoffinSpeaker \n\n\n\n\n\nMatthias EiberSpeaker \n\n\n\n\n\n\n\n\n\n \n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/nuclear-medicine-related-highlights-from-esmo-2025/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251114T133000
DTEND;TZID=Europe/Vienna:20251114T143000
DTSTAMP:20260421T154811
CREATED:20241017T081732Z
LAST-MODIFIED:20251112T090155Z
UID:1942-1763127000-1763130600@esmit.eanm.org
SUMMARY:Paediatric Thyroid Cancer
DESCRIPTION:This webinar aims to underly the most relevant differences with the adults DCT regarding epidemiology\, genetics\, pathology\, immunoistopathology\, diagnostic tools and treatment\, especially for RAI theranostic procedure. Additionally\, the webinar will also go over the main GL recommendations\, as well as present and discuss two emblematic or tricky cases. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\n\nThe aim of this course is to sensitise the attendees about the correct way to recognise\, diagnose and treat DTC in children.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\n\nPhysicians\, residents with special interest on endocrinlogy and endo-oncology\, nuclear medicine specialists\, nurses and technicians of nuclear medicine units.\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nSuggested Readings\n\n\n\n \n\n\n\n \n\n\n\n\nFrancis GL\, Waguespack SG\, Bauer AJ\, Angelos P\, Benvenga S\, Cerutti JM\, Dinauer CA\, Hamilton J\, Hay ID\, Luster M\, Parisi MT\, Rachmiel M\, Thompson GB\, Yamashita S; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 Jul;25(7):716-59. doi: 10.1089/thy.2014.0460. PMID: 25900731; PMCID: PMC4854274.\n\n\n\nLebbink CA\, Links TP\, Czarniecka A\, Dias RP\, Elisei R\, Izatt L\, Krude H\, Lorenz K\, Luster M\, Newbold K\, Piccardo A\, Sobrinho-Simões M\, Takano T\, Paul van Trotsenburg AS\, Verburg FA\, van Santen HM. 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022 Nov 29;11(6):e220146. doi: 10.1530/ETJ-22-0146. PMID: 36228315; PMCID: PMC9716393.\n\n\n\nCzarniecka A\, Woźniak G\, Kropińska A\, Jarząb B\, Handkiewicz-Junak D. Surgical approach to differentiated thyroid cancers (DTC) in children [Specyfika leczenia chirurgicznego zróżnicowanych raków tarczycy (ZRT) u dzieci]. Endokrynol Pol. 2019;70(4):357-366. doi: 10.5603/EP.a2019.0033. PMID: 31489960.\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n\n\nDesiree DeandreisSpeaker \n\n\n\n\n\nCatia OliantiModerator \n\n\n\n\n\nLivia LamartinaSpeaker \n\n\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/paediatric-thyroid-cancer/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251120T090000
DTEND;TZID=Europe/Vienna:20251121T123000
DTSTAMP:20260421T154811
CREATED:20241017T084331Z
LAST-MODIFIED:20250929T122752Z
UID:1966-1763629200-1763728200@esmit.eanm.org
SUMMARY:Focus on FDG PET/CT in Inflammatory and Infectious Diseases
DESCRIPTION:Inflammation comes from the Latin word inflammare\, to ignite or to set on fire – we want to ignite your interest in imaging inflammation and infection. \n\n\n\nInflammatory and infectious diseases can be clinically challenging. Many are systemic with highly variable clinical presentations and sometimes vague and non-specific symptoms and findings. Association with implanted material like artificial heart valves\, joint or vascular prostheses may hamper imaging or give rise to non-specific findings. \n\n\n\nAlthough the imaging strategy may still be considered unclarified in some settings\, [18F]FDG-PET/CT is now established as a key modality in the diagnostic workup of several inflammatory and infectious diseases. The course aims to provide the participants with an overview of the evidence and practical use of [18F]FDG-PET/CT in suspected inflammation and infection and covers the most well-established indications.  \n\n\n\nLed by European experts\, the sessions mix short overview lectures with interactive sessions to allow participants to engage in discussions and exchange experiences on daily practices with each other and the faculty. \n\n\n\nRegister nowThe course is fully booked. Please contact us at esmit@eanm.org if you would like to be added to the waiting list! \n\n\n\n\n\n\n\n\nLearning Objectives\n\n\n\n\nTo provide general insights into the use of [18F]FDG PET/CT in suspected or manifest inflammation and infection\, e.g. patient preparation and protocols\n\n\n\nTo provide insights into how and when to use [18F]FDG PET/CT in suspected or manifest specific inflammatory diseases\, e.g. vasculitis\, polymyalgia rheumatica\, other reumatologic diseases\, and  sarcoidosis\n\n\n\nTo provide insights into how and when to use [18F]FDG PET/CT in suspected or manifest specific infectious diseases\, e.g. fever and inflammation of unknown origin\, blood stream infections\, osteomyelitis and spondylodiscitis\, cardiac and vascular infections\n\n\n\nTo provide some insights into novel developments with this domain\, e.g. FAPI\, bacteria-specific tracers\, and long axial field of view scanners\n\n\n\nTo facilitate an open discussion on pro and cons of [18F]FDG PET/CT in suspected or manifest inflammation and infections\n\n\n\n\n\n\nTarget Audience\n\n\n\nNuclear medicine specialists with basic experience in reading [18F]FDG-PET/CT in inflammatory and infectious diseases.  \n\n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSoren HessSpeakerOdense\, Denmark \n\n\n\n\n\nOlivier GheysensSpeakerBrussels\, Belgium \n\n\n\n\n\nAyah NawwarSpeakerBristol\, UK \n\n\n\n\n\nGiorgio TregliaSpeakerLugano\, Switzerland \n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/focus-on-fdg-pet-ct-in-inflammatory-and-infectious-diseases/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Clinical Nuclear Medicine,Onsite Course
END:VEVENT
END:VCALENDAR